HBM HEALTHCARE INVESTMENTS AG Financials HBM Healthcare Investments AG
Equities
HBMN
CH0012627250
Investment Management & Fund Operators
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 208.5 CHF | +2.96% |
|
+0.24% | +14.18% |
| May. 28 | HBM Healthcare Flags NAV Boost from Yellow Jersey-Johnson & Johnson Deal | MT |
| May. 23 | HBM Healthcare Investments' Portfolio Company to Buy Laboratorios Biopas Group | MT |
Valuation
| Fiscal Period: March | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 1,320 | 2,313 | 1,920 | 1,489 | 1,338 | 1,441 | - | - |
| Enterprise Value (EV) 1 | 1,320 | 2,409 | 2,064 | 1,632 | 1,338 | 1,324 | 1,315 | 1,302 |
| P/E ratio | 7.24 x | 3.06 x | -24.6 x | -10.2 x | -2,766 x | 28.8 x | 13.6 x | 13.4 x |
| Yield | 4.05% | 3.76% | 3.51% | 3.5% | - | 3.45% | 3.8% | 3.8% |
| Capitalization / Revenue | - | - | -51.2 x | -12.8 x | 56.2 x | 18.7 x | 10.9 x | 10.7 x |
| EV / Revenue | - | - | -55 x | -14 x | 56.2 x | 17.2 x | 9.94 x | 9.69 x |
| EV / EBITDA | 7.13 x | 3.18 x | -27.4 x | -11.2 x | -520 x | 25.6 x | 12.3 x | 11.9 x |
| EV / FCF | -20.6 x | 43.2 x | -34.3 x | 18.3 x | - | 20.4 x | 20.3 x | 18.6 x |
| FCF Yield | -4.86% | 2.31% | -2.92% | 5.46% | - | 4.9% | 4.94% | 5.37% |
| Price to Book | 1.01 x | 1.08 x | 0.97 x | 0.84 x | - | 0.85 x | 0.82 x | 0.8 x |
| Nbr of stocks (in thousands) | 6,947 | 6,957 | 6,957 | 6,957 | 6,911 | 6,911 | - | - |
| Reference price 2 | 190.0 | 332.5 | 276.0 | 214.0 | 193.6 | 208.5 | 208.5 | 208.5 |
| Announcement Date | 5/8/20 | 5/27/21 | 5/18/22 | 5/26/23 | 5/8/24 | - | - | - |
1CHF in Million2CHF
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: March | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | -37.5 | -116.5 | 23.79 | 76.9 | 132.3 | 134.4 |
| EBITDA 1 | 185.1 | 758.7 | -75.31 | -146.1 | -2.574 | 51.7 | 107.1 | 109.3 |
| EBIT 1 | 185.1 | 758.7 | -75.31 | -146.1 | -2.574 | 51.7 | 107.1 | 109.3 |
| Operating Margin | - | - | 200.85% | 125.35% | -10.82% | 67.23% | 80.95% | 81.32% |
| Earnings before Tax (EBT) 1 | 182.7 | 756.3 | -78.03 | -145.3 | -0.487 | 51.7 | 107.1 | 109.3 |
| Net income 1 | 183 | 756.3 | -78.03 | -145.3 | -0.487 | 51.7 | 107.1 | 109.3 |
| Net margin | - | - | 208.1% | 124.67% | -2.05% | 67.23% | 80.95% | 81.32% |
| EPS 2 | 26.26 | 108.7 | -11.22 | -20.98 | -0.0700 | 7.240 | 15.29 | 15.60 |
| Free Cash Flow 1 | -64.16 | 55.77 | -60.2 | 89.12 | - | 64.9 | 64.9 | 69.9 |
| FCF margin | - | - | 160.54% | -76.48% | - | 84.4% | 49.06% | 52.01% |
| FCF Conversion (EBITDA) | - | 7.35% | - | - | - | 125.53% | 60.6% | 63.95% |
| FCF Conversion (Net income) | - | 7.37% | - | - | - | 125.53% | 60.6% | 63.95% |
| Dividend per Share 2 | 7.700 | 12.50 | 9.700 | 7.500 | - | 7.190 | 7.920 | 7.920 |
| Announcement Date | 5/8/20 | 5/27/21 | 5/18/22 | 5/26/23 | 5/8/24 | - | - | - |
1CHF in Million2CHF
Estimates
Balance Sheet Analysis
| Fiscal Period: March | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | 96.2 | 144 | 143 | - | - | - | - |
| Net Cash position 1 | - | - | - | - | - | 117 | 126 | 139 |
| Leverage (Debt/EBITDA) | - | 0.1268 x | -1.906 x | -0.982 x | - | - | - | - |
| Free Cash Flow 1 | -64.2 | 55.8 | -60.2 | 89.1 | - | 64.9 | 64.9 | 69.9 |
| ROE (net income / shareholders' equity) | - | - | - | - | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - | - |
| Book Value Per Share 2 | 188.0 | 309.0 | 286.0 | 255.0 | - | 245.0 | 253.0 | 260.0 |
| Cash Flow per Share | - | - | - | - | - | - | - | - |
| Capex | - | - | - | - | - | - | - | - |
| Capex / Sales | - | - | - | - | - | - | - | - |
| Announcement Date | 5/8/20 | 5/27/21 | 5/18/22 | 5/26/23 | 5/8/24 | - | - | - |
1CHF in Million2CHF
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
D+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
208.5
CHF
Average target price
236
CHF
Spread / Average Target
+13.19%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +14.18% | 1.61B | |
| +18.72% | 3.16B | |
| +12.50% | 1.76B | |
| -11.54% | 1.21B | |
| +22.48% | 813M | |
| +6.81% | 647M | |
| +40.10% | 597M | |
| +44.88% | 527M | |
| -4.17% | 506M | |
| +103.82% | 375M |
- Stock Market
- Equities
- HBMN Stock
- Financials HBM Healthcare Investments AG
